"The test is designed to assess a patient's individualized risk of sentinel lymph node positivity and recurrence or metastasis, integrating tumor biology with clinical and pathological features via a validated proprietary algorithm."

The post FDA Grants Breakthrough Status to Melanoma Test appeared first on Healthcare Communications Network.